Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02678572 · ClinicalTrials.gov registry record · Phase 3
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
A Phase 3 study, sponsored by Delcath Systems.
- Completed
- Registry status
- Phase 3
- Development phase
- 102
- Enrollment target
NCT02678572: Completed Phase 3 study, sponsored by Delcath Systems.
NCT02678572 is a Phase 3 study that has completed, run by Delcath Systems. The registered enrollment target is 102 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02678572, a Phase 3 study, has completed, sponsored by Delcath Systems.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 102 participants
- Enrollment target
Study Summary
This study will evaluate patients who have melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatment, and will be followed until death. This study will evaluate the safety and effects of the treatment on how long patients live and how long it takes for the cancer to advance or respond to the treatment.
Primary Outcome
ORR (complete or partial response)
Interventions
- COMBINATION_PRODUCT Melphalan/HDS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2023-08-15 |
| Phase | Phase 3 |
What the finished NCT02678572 record still lists
NCT02678572 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which Melphalan/HDS is the first listed.
NCT02678572 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02678572 about?
NCT02678572 is a clinical study titled "Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma". This study will evaluate patients who have melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatment, and will be followed until death. This study will evaluate the safety and effects of the treatment on how long patients liv...
What is the current status of trial NCT02678572?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 102 participants. The study started on 2016-02-01. Estimated completion is 2023-08-15.
What interventions are being tested in trial NCT02678572?
The interventions under investigation include: Melphalan/HDS (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT02678572?
This trial is sponsored by Delcath Systems, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02678572's enrollment target sits among peer trials
102 1676th of 2000 higher than 321 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI